Lung cancer drug taken off German market because of no additional benefit rating
On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with
Category: Pricing
German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
Do you know your way around the Lauer Taxe? – A quick-start help guide
The Lauer Taxe is a database of all pharmaceutical entities, e.g. drugs, medical devices and also remedies, and their prices.
The four most important things to know about pricing in Germany
Currently, in Germany, free pricing applies in the first year. This means, at the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a new chemical entity (NCE). This price is then valid for the first 12 months from the day of launch.
Prof. Dr. Karl Lauterbach is the new German health minister
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot